Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)

The University of Texas System (UT)

Status and phase: Enrolling; Early Phase 1

Conditions: Hypertension; Obesity

Treatments: Drug: Neuropeptide Y

Study type: Interventional

Funder types: Other

Identifiers

NCT04838678

STU2020-0749

Details and patient eligibility

About

The purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. The study will also investigate how hypertension and obesity influence the nervous system and vascular function. The study will involve measuring sympathetic nervous system activity and blood flow during common laboratory physiological stress protocols (e.g. hypoxia, exercise), and in response to infusion of drugs that cause vasodilation or vasoconstriction.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Control - BMI<30, age 18-55
• Hypertensive - BMI<30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring Obese- BMI>30, age 18-55 Obese-hypertensive- BMI>30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring

Exclusion criteria

All groups - presence of other significant cardiovascular disease, renal disease, history of smoking, diabetes,

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 4 patient groups

Healthy Control

Experimental group

Description:

Healthy age matched controls with no history of cardiovascular disease and normal bodyweight

Treatment:

Drug: Neuropeptide Y

Hypertensive

Experimental group

Description:

Hypertensive adults who are not obese

Treatment:

Drug: Neuropeptide Y

Obese

Experimental group

Description:

Obese adults who are not hypertensive

Treatment:

Drug: Neuropeptide Y

Obese-hypertensive

Experimental group

Description:

Obese adults who are being treated for hypertension

Treatment:

Drug: Neuropeptide Y